Avellone G, Di Garbo V, Strano A
Clin Ter. 1989 Apr 15;129(1):25-9.
The results are reported of a double-blind crossover trial intended to evaluate the effectiveness and safety of a new aryloxy derivative compared to placebo. Twenty patients with hyperlipidemia not responding to dietary treatment received either one capsule of the active substance or of placebo (200 mg) three times daily for 16 weeks. Total cholesterol, HDL and triglycerides showed the following changes at the of the treatment period: -11%, +6% and -48% with clinofibrate and -1%, -4% and -1% during control periods. The substance was well tolerated; only in one patient clinofibrate was withdrawn as a precaution in view of the onset of medium severe diarrhea and abdominal pain.
报告了一项双盲交叉试验的结果，该试验旨在评估一种新的芳氧基衍生物与安慰剂相比的有效性和安全性。20名对饮食治疗无反应的高脂血症患者，每天三次，每次服用一粒活性物质胶囊或安慰剂（200毫克），持续16周。在治疗期结束时，总胆固醇、高密度脂蛋白和甘油三酯出现了以下变化：氯贝丁酯治疗时分别为-11%、+6%和-48%，对照期分别为-1%、-4%和-1%。该物质耐受性良好；仅一名患者因出现中度严重腹泻和腹痛，作为预防措施停用了氯贝丁酯。
